ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31

Eton Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$49.22−1.09 (-2.17%)

Close on Oct 19, 2026

Market cap: $1.61B
P/E (TTM): 126.2
Dividend yield: –

Eton Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	80	39	32	21	22	0.04	0.96	–
Cost of Revenue	37	16	11	6.93	2.83	0.44	0.45	–
Gross Profit	43	23	21	14	19	-0.40	0.51	–
Research & Development	7.77	3.26	3.32	4.00	6.24	14	12	5.63
General & Administrative	36	23	19	19	14	13	7.55	4.69
Operating Expenses	44	26	22	23	21	27	19	10
Operating Income	-0.84	-2.60	-1.19	-8.26	-1.50	-27	-19	-10
Interest Expense	4.78	2.01	1.06	0.96	1.04	0.88	0.10	–
Other Non-Operating Income	-3.71	-1.21	0.50	-0.76	-1.01	-0.86	0.28	0.16
Asset Impairment Charges	0	0	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	–	–	0	0	0.18	–	–	–
Pretax Income	-4.56	-3.81	-0.69	-9.02	-1.96	-28	-18	-13
Income Tax Expense	0.04	0.02	0.25	0	0	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	-13
Net Income	-4.60	-3.82	-0.94	-9.02	-1.96	-28	-18	-13
Preferred Dividends	–	–	–	–	–	–	–	24
Net Income to Common	–	–	–	–	–	-28	-18	-37
EPS (Basic)(per share)	-0.17	-0.15	-0.04	-0.36	-0.08	-1.33	-1.03	-5.80
EPS (Diluted)(per share)	–	–	–	–	-0.08	-1.33	-1.03	-5.80
Shares Outstanding (Basic, Weighted)(shares)	27	26	26	25	25	21	18	6.42
Shares Outstanding (Diluted, Weighted)(shares)	27	26	26	25	25	21	18	6.42
EBITDA	3.20	-1.45	-0.29	-6.49	-1.03	-27	-18	-10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 57.9%
Operating margin: 15.4%
Net margin: 12.0%
Return on equity, FY2025: -18.2%

Financial strength

Current ratio: 1.52
Debt to equity: 0.60
Debt to assets: 24.1%
Cash to current liabilities: 59.5%

Valuation

P/E ratio: 126.2
Price to sales: 15.28
Price to book: 34.64
Dividend yield: –